Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

Journal of Neurology

Volumn 263, Issue 9, 2016, Pages 1778-1787

  Newsome, Scott D ^a,f   Kieseier, Bernd C ^b,c   Arnold, Douglas L ^d,e   Shang, Shulian ^c   Liu, Shifang ^c   Hung, Serena ^c   Sabatella, Guido ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Orthopedic Surgery   (Germany)

^c BIOGEN   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e NEURORX RESEARCH   (Canada)

^f JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Clinical trial; Interferon; Multiple sclerosis; Peginterferon beta 1a; Pegylated; Phase 3; Relapsing remitting

Indexed keywords

PEGINTERFERON BETA1A; BETA INTERFERON; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SENSITIVITY ANALYSIS; ADOLESCENT; CLINICAL TRIAL; DISABILITY; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERNATIONALITY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYETHYLENE GLYCOLS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975136177     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8182-4     Document Type: Article

References (8)

1. Kieseier BC, Calabresi PA (2012) PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis. CNS Drugs 26(3):205–214
2. Baker DP, Pepinsky RB, Brickelmaier M, Gronke RS, Hu X, Olivier K, Lerner M, Miller L, Crossman M, Nestorov I, Subramanyam M, Hitchman S, Glick G, Richman S, Liu S, Zhu Y, Panzara MA, Davar G (2010) PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res 30(10):777–785
3. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, on behalf of the ADVANCE Study Investigators (2014) Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13(7):657–665
4. Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA (2015) Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 21(8):1025–1035
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352(9139):1498–1504
7. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43(4):655–661
8. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7):1268–1276